Jeong Hye Yun, Lee So-Young, Kim Sang Hoon, Kim Jinkwon
Division of Nephrology, Department of Internal Medicine, CHA Bundang Medical Center, CHA University School of Medicine, Seongnam, Korea.
Division of Cardiology, Department of Internal Medicine CHA Bundang Medical Center, CHA University School of Medicine, Seongnam, Korea.
Patient Prefer Adherence. 2020 Apr 5;14:717-724. doi: 10.2147/PPA.S245324. eCollection 2020.
Despite indubitable evidence for the cardiovascular benefits of statins, there have been concerns that statin discontinuation may cause negative effects known as "statin withdrawal syndrome." This study aimed to assess the benefit and the withdrawal effect of statins after percutaneous coronary intervention (PCI).
We conducted a retrospective cohort study on 5218 patients who underwent PCI between 2002 and 2013 using the nationwide health insurance claim data in Korea. Based on the prescription data, the use of statins during follow-up was classified into three risk periods: "statin period" (period with statin cover), "statin withdrawal period" (withdrawal of statin within 30 days), and "no statin period" (no exposure to statin for longer than 30 days). The primary outcome was the composite outcome of myocardial infarction, coronary revascularization, stroke, and all-cause death. We performed multivariate Cox proportional regression analyses which treated the use of statins as a time-dependent variable.
During the follow-up period of 3.54 ± 2.91 years (mean ± standard deviation), 1515 (29.0%) patients sustained a primary outcome. Compared with the "no statin period," the "statin period" was associated with lower risk of the primary outcome (adjusted hazard ratio [HR] 0.72, 95% confidence interval [CI, 0.63-0.81]). While the "statin withdrawal period" posed a significantly increased risk (adjusted HR 1.87, 95% CI [1.52-2.29]). With respect to the intensity of statins associated with withdrawal, dose-dependent increased risk was observed for withdrawal of low-, moderate-, and high-intensity statins; adjusted HR [95% CI] were 1.45 [0.74-2.86], 1.86 [1.49-2.32], and 2.61 [1.41-4.81], respectively.
After PCI, there was an increased cardiovascular risk during the statin withdrawal period, especially with the use of high-intensity statins. To maximize the beneficial effect and to avoid the withdrawal effect of statins, high-risk patients need to adhere to taking statins without discontinuation.
尽管他汀类药物对心血管有益的证据确凿,但人们一直担心停用他汀类药物可能会产生被称为“他汀类药物撤药综合征”的负面影响。本研究旨在评估经皮冠状动脉介入治疗(PCI)后他汀类药物的益处和撤药效应。
我们利用韩国全国健康保险索赔数据,对2002年至2013年间接受PCI的5218例患者进行了一项回顾性队列研究。根据处方数据,随访期间他汀类药物的使用分为三个风险期:“他汀类药物期”(有他汀类药物覆盖的时期)、“他汀类药物撤药期”(30天内停用他汀类药物)和“无他汀类药物期”(未接触他汀类药物超过30天)。主要结局是心肌梗死、冠状动脉血运重建、中风和全因死亡的复合结局。我们进行了多变量Cox比例回归分析,将他汀类药物的使用作为一个时间依赖性变量。
在3.54±2.91年(均值±标准差)的随访期内,1515例(29.0%)患者出现主要结局。与“无他汀类药物期”相比,“他汀类药物期”主要结局风险较低(调整后风险比[HR]0.72,95%置信区间[CI,0.63 - 0.81])。而“他汀类药物撤药期”风险显著增加(调整后HR 1.87,95% CI [1.52 - 2.29])。关于与撤药相关的他汀类药物强度,低、中、高强度他汀类药物撤药时均观察到剂量依赖性风险增加;调整后HR [95% CI]分别为1.45 [0.74 - 2.